Overview of BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer (NMIBC)
Neal Shore, MD, FACS, provides an overview of BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC), with a focus on patient presentation and risk stratification.
EP: 1.Overview of BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer (NMIBC)
EP: 2.Treating Patients With High-Risk BCG-Unresponsive NMIBC
EP: 3.SunRISe-1: TAR-200 and Cetrelimab in Patients With High-Risk NMIBC
EP: 4.Ongoing Research in BCG-Unresponsive NMIBC
EP: 5.What Are the Advantages of TAR-200 in BCG-Unresponsive NMIBC?
EP: 6.Emerging Agents in BCG-Unresponsive NMIBC
EP: 7.Optimizing Patient Selection and Treatment Sequencing in BCG-Unresponsive NMIBC
This is a video synopsis/summary of an Investigator Perspectives featuring Neal Shore, MD, FACS.
Dr Neal Shore discusses the intravesical therapy bacillus Calmette-Guérin (BCG), an attenuated form of Mycobacterium bovis bacteria, which has been the standard of care for treating non–muscle-invasive bladder cancer (NMIBC) for multiple decades thanks to pioneering work by Dr Pablo Morales. BCG is typically administered weekly for 6 weeks as an induction course. For patients with high-risk NMIBC, including those with high-grade papillary disease, T1 invasion into the basement membrane (also known as the lamina propria), carcinoma in situ, or a combination, maintenance doses are given for up to 3 years based on the SWOG trial demonstrating reduced recurrence and progression rates.
Due to BCG shortages over recent years, Dr Shore generally reserves BCG for high-risk NMIBC patients. Classic BCG-unresponsive disease is defined as persistent disease after at least 2 consecutive induction courses with at least 5 of 6 doses (or persistent disease after induction) plus at least 2 of 3 maintenance doses at 3 and 6 months.
Patients with BCG-unresponsive high-risk NMIBC can present with gross hematuria, usually with initial or terminal blood, or microscopic hematuria, defined as more than 3 red blood cells per high-power field. Risk factors to identify patients warranting evaluation include smoking, alcohol use, exposures to industrial or environmental pollution, and possibly family history. Many patients with idiopathic microscopic hematuria will not develop bladder cancer.
Video synopsis is AI-generated and reviewed by Urology Times® editorial staff.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
Nadofaragene firadenovec shows durable efficacy in NMIBC
April 8th 2024"In this follow-up analysis of the phase 3 study, we demonstrated a sustained response to Adstiladrin treatment over 3 years, allowing more than half of the patients in the study to remain cystectomy free for at least 36 months,” says Colin P.N. Dinney, MD.
